182 related articles for article (PubMed ID: 4599330)
41. Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma.
Kirkwood JM; Mascari RA; Edington HD; Rabkin MS; Day RS; Whiteside TL; Vlock DR; Shipe-Spotloe JM
Cancer; 2000 Jun; 88(12):2693-702. PubMed ID: 10870051
[TBL] [Abstract][Full Text] [Related]
42. Immunology and cutaneous malignant melanoma.
Sober AJ
Int J Dermatol; 1976; 15(1):1-18. PubMed ID: 1107238
[No Abstract] [Full Text] [Related]
43. Anti-tumor immunoreactivity in patients with malignant melanoma.
Nairn RC; Nind AP; Guli EP; Davies DJ; Little JH; Davis NC; Whitehead RH
Med J Aust; 1972 Feb; 1(9):397-403. PubMed ID: 4554232
[No Abstract] [Full Text] [Related]
44. Use of formalin-fixed melanoma cells for the detection of antibodies against surface antigens by a micro-immune adherence technique.
Müller C; Sorg C
Eur J Immunol; 1975 Mar; 5(3):175-8. PubMed ID: 1234054
[TBL] [Abstract][Full Text] [Related]
45. [Characterization of the infiltration of human malignant melanoma according to the nautre of the receiving surface. II. Study of tumor cell extracts].
Roubin R; Cesarini JP; Fridman WH; Mouly R
Ann Dermatol Syphiligr (Paris); 1976; 103(3):316-20. PubMed ID: 795368
[No Abstract] [Full Text] [Related]
46. Characterization of suppressor cells in mice with a transplantable malignant melanoma.
Stelzer GT; Wallace JH
Oncology; 1980; 37(6):397-405. PubMed ID: 6448970
[TBL] [Abstract][Full Text] [Related]
47. Spontaneous regression of malignant melanoma. Pathologic and immunologic study in a ten year survivor.
Maurer H; McIntyre OR; Rueckert F
Am J Surg; 1974 Apr; 127(4):397-403. PubMed ID: 4274502
[No Abstract] [Full Text] [Related]
48. Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma.
Murray JL; Gillogly M; Kawano K; Efferson CL; Lee JE; Ross M; Wang X; Ferrone S; Ioannides CG
Cancer Res; 2004 Aug; 64(15):5481-8. PubMed ID: 15289358
[TBL] [Abstract][Full Text] [Related]
49. Melanoma antibodies: specificity and interaction with melanoma and cytotoxic T-cells.
Dippold WG; Knuth A; Meyer zum Büschenfelde KH
Behring Inst Mitt; 1984 May; (74):14-8. PubMed ID: 6332614
[TBL] [Abstract][Full Text] [Related]
50. [The reaction of the T-immunity system in patients with malignant skin melanoma and stomach cancer to active nonspecific immunotherapy].
Glinkina LS; Bruvere RZh
Vopr Onkol; 1992; 38(6):659-66. PubMed ID: 1300766
[TBL] [Abstract][Full Text] [Related]
51. Demonstration of two distinct antigens in spent tissue culture medium of a human malignant melanoma cell line.
Gupta RK; Irie RF; Chee DO; Kern DH; Morton DL
J Natl Cancer Inst; 1979 Aug; 63(2):347-56. PubMed ID: 88538
[No Abstract] [Full Text] [Related]
52. Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients.
McCarter MD; Baumgartner J; Escobar GA; Richter D; Lewis K; Robinson W; Wilson C; Palmer BE; Gonzalez R
Ann Surg Oncol; 2007 Oct; 14(10):2854-60. PubMed ID: 17593331
[TBL] [Abstract][Full Text] [Related]
53. Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma.
Hillen F; Baeten CI; van de Winkel A; Creytens D; van der Schaft DW; Winnepenninckx V; Griffioen AW
Cancer Immunol Immunother; 2008 Jan; 57(1):97-106. PubMed ID: 17602225
[TBL] [Abstract][Full Text] [Related]
54. In situ analysis of the mononuclear cell infiltrate in primary malignant melanoma of the skin.
Poppema S; Bröcker EB; de Leij L; Terbrack D; Visscher T; Ter Haar A; Macher E; Thé TH; Sorg C
Clin Exp Immunol; 1983 Jan; 51(1):77-82. PubMed ID: 6219841
[TBL] [Abstract][Full Text] [Related]
55. The immune response in human malignant melanoma.
Mackie RM
Clin Exp Dermatol; 1976 Mar; 1(1):23-8. PubMed ID: 773575
[No Abstract] [Full Text] [Related]
56. Peptide vaccine trials for melanoma: preclinical background and clinical results.
Talebi T; Weber JS
Semin Cancer Biol; 2003 Dec; 13(6):431-8. PubMed ID: 15001162
[No Abstract] [Full Text] [Related]
57. Cytotoxicity of human rosette-forming blood lymphocytes on cultivated human tumor cells.
Wybran J; Hellström I; Hellström KE; Fudenberg HH
Int J Cancer; 1974 Apr; 13(4):515-21. PubMed ID: 4546321
[No Abstract] [Full Text] [Related]
58. [Dermatitis ulcerosa (pyoderma gangraenosum). 2 cases with abnormal serum factors].
Kovács L; Husz S; Dobozy A; Szarbó E
Z Hautkr; 1976 May; 51(09):571-81. PubMed ID: 785845
[No Abstract] [Full Text] [Related]
59. Immunologic mechanisms in malignant melanoma of the skin.
Cochran AJ
Trans Ophthalmol Soc U K (1962); 1977 Sep; 97(3):385-8. PubMed ID: 347641
[No Abstract] [Full Text] [Related]
60. [Current aspects of melanoma research. I. Classification, immunology].
Wätzig V
Dermatol Monatsschr; 1977 May; 163(5):353-8. PubMed ID: 301834
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
